1. Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
- Author
-
Mo'tasem M Alsmadi, Raghda Nasry Sabat, Rawda Yaseen AlSheyyab, Rafeef Khalid Masaedeh, Bashar Al-Taani, and Rana Mohammad Obeidat
- Subjects
medicine.medical_treatment ,Pharmaceutical Science ,Peptide ,02 engineering and technology ,Gonadotropin-releasing hormone ,Pharmacology ,030226 pharmacology & pharmacy ,Gonadotropin-Releasing Hormone ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Breast cancer ,Hormone Antagonists ,medicine ,Animals ,Humans ,Degarelix ,chemistry.chemical_classification ,Dosage Forms ,Inhalation ,Chemistry ,Drug Administration Routes ,021001 nanoscience & nanotechnology ,medicine.disease ,Amino acid ,Ovulation induction ,0210 nano-technology - Abstract
GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
- Published
- 2017